Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PO-53 - Prospective evaluation of risk assessment models and biological markers of hypercoagulability for the identification of high VTE risk patients with lung adenocarcinoma. The ROADMAP study.
Boura P, Evmorfiadis I, Rousseau A, Charpidou A, Giozos G, Van Dreden P, Syrigos K, Larsen A, Elalamy I, Gerotziafas GT. Boura P, et al. Among authors: van dreden p. Thromb Res. 2016 Apr;140 Suppl 1:S196. doi: 10.1016/S0049-3848(16)30186-4. Epub 2016 Apr 8. Thromb Res. 2016. PMID: 27161741
Tissue factor over-expression by human pancreatic cancer cells BXPC3 is related to higher prothrombotic potential as compared to breast cancer cells MCF7.
Gerotziafas GT, Galea V, Mbemba E, Khaterchi A, Sassi M, Baccouche H, Prengel C, van Dreden P, Hatmi M, Bernaudin JF, Elalamy I. Gerotziafas GT, et al. Among authors: van dreden p. Thromb Res. 2012 Jun;129(6):779-86. doi: 10.1016/j.thromres.2011.07.049. Epub 2011 Sep 13. Thromb Res. 2012. PMID: 21917301
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K, Grapsa D, Sangare R, Evmorfiadis I, Larsen AK, Van Dreden P, Boura P, Charpidou A, Kotteas E, Sergentanis TN, Elalamy I, Falanga A, Gerotziafas GT. Syrigos K, et al. Among authors: van dreden p. Oncologist. 2018 Nov;23(11):1372-1381. doi: 10.1634/theoncologist.2017-0530. Epub 2018 Aug 13. Oncologist. 2018. PMID: 30104289 Free PMC article.
Comparison of antithrombin-dependent and direct inhibitors of factor Xa or thrombin on the kinetics and qualitative characteristics of blood clots.
Salta S, Papageorgiou L, Larsen AK, Van Dreden P, Soulier C, Cokkinos DV, Elalamy I, Gerotziafas GT. Salta S, et al. Among authors: van dreden p. Res Pract Thromb Haemost. 2018 Jul 17;2(4):696-707. doi: 10.1002/rth2.12120. eCollection 2018 Oct. Res Pract Thromb Haemost. 2018. PMID: 30349889 Free PMC article.
Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, Psaltopoulou T, Salta S, Van Dreden P, Sangare R, Larsen AK, Terpos E, Elalamy I, Dimopoulos MA, Gerotziafas GT. Fotiou D, et al. Among authors: van dreden p. Blood Cancer J. 2018 Nov 7;8(11):102. doi: 10.1038/s41408-018-0135-y. Blood Cancer J. 2018. PMID: 30405097 Free PMC article.
86 results